CV - Inserm U919

Dr Fabian DOCAGNE, PhD
UMR-S INSERM U919
Serine Proteases and Pathophysiology of the neurovascular Unit
GIP Cyceron
Bvd H. Becquerel - BP 5229
14 074 CAEN Cedex
FRANCE
Tel: +33 (0) 231 470 102
Fax: +33 (0) 231 470 222
Email: [email protected]
Web: http://www.researchgate.net/profile/Fabian_Docagne/
Research area 1: Neuroscience
Keywords: Astrocytes, oligodendrocytes, multiple sclerosis, serine-proteases, white matter
Experience, position and employment
Fabian Docagne is a researcher (CR1 Inserm) and has been working at U919 since 2008. His main interests
are directed towards the study of glial cells in health and disease with a particular focus on tissue-plasminogen
activator (tPA).
Much of Fabian Docagne’s ongoing research has focussed on the role of tPA in white matter lesions and
animal models of multiple sclerosis.
He did his Ph.D. training (1998-2001) in the laboratory of Dr Eric MacKenzie at the French national center
for scientific research (CNRS), with a particular focus on the role of Transforming Growth Factor-β in CNS
pathologies such as stroke and Alzheimer’s disease. While some of the effects of this cytokine were driven by the
action of inhibitors of serine-proteases, his interest moved toward serine proteases -in particular, tissue-type
plasminogen activator (tPA)- and their effects in cerebral ischaemia. He then moved to Southampton University for
a one year postdoc (2001-2002) in the lab of Pr. Hugh Perry at the CNS inflammation group, where he worked on
the role of serine proteases in chronic inflammation situation such as prion disease. He next spent six years in
Spain at the Cajal Institute, for a second postdoc (2002-2008) on the topic of endocannabinoid molecules in
multiple sclerosis in the lab of Dr Carmen Guaza. Since the beginning of 2008, he is back in France to work on the
topic of serine-proteases in the neuro-glio-vascular unit.
Selection of 5 recent publications:
Krol S, Macrez R, Docagne F, Defer G, Laurent S, Rahman M, Hajipour MJ, Kehoe PG, Mahmoudi M. Therapeutic
benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood
brain barrier. Chem Rev. 2013 Mar 13;113(3):1877-903
Cassé F, Bardou I, Danglot L, Briens A, Montagne A, Parcq J, Alahari A, Galli T, Vivien D, Docagne F. Glutamate
controls tPA recycling by astrocytes, which in turn influences glutamatergic signals. J Neurosci. 2012 Apr
11;32(15):5186-99
Montagne A, Gauberti M, Macrez R, Jullienne A, Briens A, Raynaud JS, Louin G, Buisson A, Haelewyn B, Docagne F,
Defer G, Vivien D, Maubert E. Ultra-sensitive molecular MRI of cerebrovascular cell activation enables early
detection of chronic central nervous system disorders. Neuroimage. 2012 Nov 1;63(2):760-70.
Correa F, Gauberti M, Parcq J, Macrez R, Hommet Y, Obiang P, Hernangómez M, Montagne A, Liot G, Guaza C,
Maubert E, Ali C, Vivien D, Docagne F. Tissue plasminogen activator prevents white matter damage following
stroke. J Exp Med. 2011 Jun 6;208(6):1229-42.
Loría F, Petrosino S, Hernangómez M, Mestre L, Spagnolo A, Correa F, Di Marzo V, Docagne F, Guaza C. An
endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol Dis. 2010
Jan;37(1):166-76.
http://www.ncbi.nlm.nih.gov/pubmed/?term=Docagne+F